The American College of Physicians (ACP) issued updated vaccine practice points for physicians that advise adults aged 75 or older should receive a protein subunit Respiratory Syncytial Virus (RSV) ...
Biopharmaceutical company Annexon (ANNX) is showing promising results in developing treatments for inflammatory-related diseases. Its flagship candidate, ANX005, showed positive topline Phase 3 data ...
In endemic areas, dengue-related Guillain-Barre syndrome could be a 'substantial and underrecognized component of the ...
The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain-Barré syndrome (GBS), which ...
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (ANNX) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...
LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a ...
Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of Glasgow, and David Cornblath, MD, ...
Brazil: Brazilian researchers have found in a new study, published in The New England Journal of Medicine, that dengue ...
MedPage Today on MSN
Risk of Guillain–Barre syndrome rises after dengue infection
GBS occurrence was highest in the first 2 weeks after dengue symptom onset ...
A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain-Barré ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results